Connect Biopharma Holdings (CNTB) Net Margin (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Net Margin for 3 consecutive years, with 11478.11% the latest figure, recorded in Q1 2026.

• Quarterly Net Margin changed N/A year-over-year to 11478.11% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27727.9% (changed N/A YoY) and the FY2025 annual result came in at 86687.5%, down 8662747.0% from the prior year.
• Net Margin grew to 11478.11% in Q1 2026 per CNTB's latest filing, from 107500.0% in the prior quarter.
• Over the last five years, Net Margin for CNTB reached as high as 1056.28% in Q3 2024 and fell as low as 107500.0% in Q3 2025.
• A 3-year average of 29636.65% and a median of 11478.11% in 2026 frame the typical range for Net Margin.
• The largest YoY upside for Net Margin was 10644372 bps in 2025 against a maximum downside of 10644372 bps in 2025.
• Year by year, Net Margin stood at 1275.93% in 2024, then slumped by 8325 bps to 107500.0% in 2025, then soared by 89 bps to 11478.11% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 11478.11%, 107500.0%, and 26872.92% for Q1 2026, Q3 2025, and Q2 2025 respectively.